Campbell Alliance Adds Industry Veterans Jon W. McGarity and David Lilley as Executive Vice Presidents
June 17, 2009
Campbell Alliance, the leading management consulting firm specializing in the pharmaceutical and biotech industry, today announced that it has appointed industry veterans Jon W. McGarity and David Lilley as Executive Vice Presidents. Both gentlemen will work directly with John Campbell, CEO of Campbell Alliance, and the firm’s seven practice areas to advise the firm’s emerging and midsize client companies. They will focus on enhancing relationships with chief executives in those companies, as well as coordinating Campbell Alliance’s resources to help chief executives address highly strategic challenges.
Jon W. McGarity has over 40 years of experience in the pharmaceutical and biotech industry including senior management positions at GlaxoSmithKline, Bristol Myers Squibb, and Novartis (Sandoz Pharmaceuticals). During that time Mr. McGarity has served in various general management, sales, marketing, and managed care roles, having launched over 40 products and completed numerous business development deals.
David Lilley has worked to serve the pharmaceutical and biotech industry for over 30 years while in executive management positions at Johnson & Johnson; Innovex, a contract sales organization; Quintiles Transnational, the world largest global contract research organization (CRO); and NovaQuest, the investment arm of Quintiles.
“In this market environment, executive management teams at emerging and midsize companies are experiencing unprecedented challenges in the areas of clinical development, partnering, financing, and commercialization. Both Jon and David have decades of experience over-coming challenges of this nature and make great additions to the specialized consulting teams already in place at Campbell Alliance,” stated John Campbell.
Background Information on Jon W. McGarity
Most recently, Jon W. McGarity was the President and CEO of EthiX Associates, a pharmaceutical and biotech consultancy he founded in 1996. He has also served as the President and CEO of GenBioPro, Inc., a specialty biopharmaceutical company focused on the development and marketing of “biosimilar” products, and INSYS Therapeutics, Inc., a privately held biopharmaceutical company with a focus on chemotherapy induced nausea and vomiting, pain management and CNS disorders.
He held the positions of the Chairman, President, and CEO of the Arizona BioIndustry Association from 2004 to 2007.
Mr. McGarity was President and Chief Operating Officer and then Vice Chairman of Pharmaceutical Marketing Services, Inc. from 1991 to 1996.
He was employed by GlaxoSmithKline (then Glaxo) from 1987 to 1991. Over that time he served as Vice President in the Corporate Division; Vice President of National Accounts; Vice President and General Manager of the Glaxo Dermatology group; and Director of Managed Health Care.
From 1981 to 1986, Mr. McGarity worked as Vice President of Sales and Marketing at WestwoodPharmaceuticals, the specialty pharmaceuticals division of Bristol Myers Squibb.
From 1965 to 1981 he was employed by Novartis Pharmaceuticals (then Sandoz) having worked throughout the ranks of their commercial organization as a sales representative, hospital representative, product manager, district manager, and Director of Sales and Marketing in Canada and the United States.
Mr. McGarity is a Board Director at Cypress Biosciences Inc. (CYPB), and also serves on the Boards of several early stage pharma/biotech companies including Apthera, GenBioPro, SynBuild, MedApps, Inc., and Restorative Biosciences. He also sits of the Boards of a number of life science organizations and university programs including the Arizona BioIndustry Association and the Global Advisory Council at Thunderbird School of Global Management
Background Information on David Lilley
Most recently, David Lilley led the Commercial arm of NovaQuest from 2005 to 2008 where he and his team executed deals to provide services “at risk” surrounding the launch and subsequent support of products on a global basis. These efforts also involved the coordination of multiple sales and marketing services associated with Quintiles and Innovex, which was achieved through the Global Alliance Management function at Quintiles. This function also reported to Mr. Lilley.
From 1987 to 2005, Mr. Lilley served in various executive management roles including Global President at Innovex, which was acquired by Quintiles in 1996. Mr. Lilley was appointed to the Board of Directors of Innovex in 1989 and successfully moved the company into a clinical research arena initially providing clinical research associates and monitors to companies on a contract basis before becoming a full-service CRO in 1991.
Prior to his time at Innovex, Mr. Lilley worked for Johnson & Johnson in the United Kingdom for seven years, holding several marketing and sales positions at the company.
About Campbell Alliance
Campbell Alliance is the leading management consulting firm specializing in the pharmaceutical and biotechnology industry. The firm's clients include most of the world's top-20 pharmaceutical companies, as well as numerous emerging and midsize firms. Campbell Alliance is organized into practice areas, each specializing in a critical industry function: Brand Management, Business Development, Clinical Development, Managed Markets, Medical Affairs, Sales, and Trade and Distribution. From its locations in Raleigh, NC, Parsippany, NJ, Los Angeles, San Francisco, Chicago, Boston, Philadelphia, New York City, Atlanta, and London, the firm serves clients throughout North America, Europe, and Japan. For more information on Campbell Alliance, please visit http://www.campbellalliance.com.